1. Basal‐like breast cancer engages tumor‐supportive macrophages via secreted factors induced by extracellular S100A4. Issue 9 (9th August 2018) Authors: Prasmickaite, Lina; Tenstad, Ellen M.; Pettersen, Solveig; Jabeen, Shakila; Egeland, Eivind V.; Nord, Silje; Pandya, Abhilash; Haugen, Mads H.; Kristensen, Vessela N.; Børresen‐Dale, Anne‐Lise; Engebråten, Olav; Mælandsmo, Gunhild M. Journal: Molecular oncology Issue: Volume 12:Issue 9(2018) Page Start: 1540 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study. (3rd August 2022) Authors: Ree, Anne Hansen; Mælandsmo, Gunhild M.; Flatmark, Kjersti; Russnes, Hege G.; Gómez Castañeda, Mónica; Aas, Eline Journal: Acta oncologica Issue: Volume 61:Number 8(2022) Page Start: 955 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Design, synthesis and biological evaluation of 6‐substituted quinolines derived from cabozantinib as c‐Met inhibitors. Issue 9 (15th August 2019) Authors: Lien, Vegard Torp; Pettersen, Solveig; Haugen, Mads Haugland; Olberg, Dag Erlend; Mælandsmo, Gunhild M.; Klaveness, Jo Journal: Archiv der Pharmazie Issue: Volume 352:Issue 9(2019) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen. Issue 8 (1st May 2021) Authors: Barkovskaya, Anna; Goodwin, Craig M.; Seip, Kotryna; Hilmarsdottir, Bylgja; Pettersen, Solveig; Stalnecker, Clint; Engebraaten, Olav; Briem, Eirikur; Der, Channing J.; Moestue, Siver A.; Gudjonsson, Thorarinn; Mælandsmo, Gunhild M.; Prasmickaite, Lina Journal: Molecular oncology Issue: Volume 15:Issue 8(2021) Page Start: 2026 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Dynamic 18F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts. (October 2013) Authors: Kristian, Alexandr; Revheim, Mona Elisabeth; Qu, Hong; Mælandsmo, Gunhild M.; Engebråten, Olav; Seierstad, Therese; Malinen, Eirik Journal: Acta oncologica Issue: Volume 52:Number 7(2013) Page Start: 1566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. From autonomy to community; new perspectives on tumorigenicity and therapy resistance. Issue 10 (December 2015) Authors: Skrbo, Nirma; Tenstad, Ellen; Mælandsmo, Gunhild M.; Sørlie, Therese; Andersen, Kristin Journal: Cancer treatment reviews Issue: Volume 41:Issue 10(2015) Page Start: 809 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Issue 12 (14th June 2021) Authors: Nunes‐Xavier, Caroline E.; Kildal, Wanja; Kleppe, Andreas; Danielsen, Håvard E.; Wæhre, Håkon; Llarena, Roberto; Mælandsmo, Gunhild M.; Fodstad, Øystein; Pulido, Rafael; López, José I. Journal: Prostate Issue: Volume 81:Issue 12(2021) Page Start: 838 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. In Vivo 31P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts. Issue 3 (14th February 2014) Authors: Esmaeili, Morteza; Moestue, Siver A.; Hamans, Bob C.; Veltien, Andor; Kristian, Alexandr; Engebråten, Olav; Mælandsmo, Gunhild M.; Gribbestad, Ingrid S.; Bathen, Tone F.; Heerschap, Arend Journal: Journal of magnetic resonance imaging Issue: Volume 41:Issue 3(2015) Page Start: 601 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Low‐molecular contrast agent dynamic contrast‐enhanced (DCE)‐MRI and diffusion‐weighted (DW)‐MRI in early assessment of bevacizumab treatment in breast cancer xenografts. Issue 5 (21st March 2013) Authors: Moestue, Siver A.; Huuse, Else M.; Lindholm, Evita M.; Bofin, Anna; Engebraaten, Olav; Mælandsmo, Gunhild M.; Akslen, Lars A.; Gribbestad, Ingrid S. Journal: Journal of magnetic resonance imaging Issue: Volume 38:Issue 5(2013) Page Start: 1043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Low‐molecular contrast agent dynamic contrast‐enhanced (DCE)‐MRI and diffusion‐weighted (DW)‐MRI in early assessment of bevacizumab treatment in breast cancer xenografts. Issue 5 (21st March 2013) Authors: Moestue, Siver A.; Huuse, Else M.; Lindholm, Evita M.; Bofin, Anna; Engebraaten, Olav; Mælandsmo, Gunhild M.; Akslen, Lars A.; Gribbestad, Ingrid S. Journal: Journal of magnetic resonance imaging Issue: Volume 38:Issue 5(2013) Page Start: 1043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗